Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
Date:3/19/2012

RALEIGH, N.C., March 19, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2011, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of the Company's achievements and an update on business operations and upcoming milestones for 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110217/CL49801LOGO

In 2011, BDSI made significant strides in progressing development of its two lead products, BEMA Buprenorphine for chronic pain and BEMA Buprenorphine/Naloxone (BNX) for opioid dependence.  As such, but as expected, BDSI increased its expenditures and therefore reported a net loss of $23.3 million, or ($0.82) per share, for the twelve months ending December 31, 2011, as compared to a net loss of $13.0 million, or $(0.56) per share, for the twelve months ending December 31, 2010.  The increased net loss is due primarily to increased research and development expenses which totaled $20.8 million in 2011, compared to $10.6 million in 2010. Conduct of the Phase 3 trial for BEMA Buprenorphine in chronic pain and initial studies for BNX are primarily responsible for higher research and development expenses in 2011. 

At December 31, 2011, BDSI had $10.8 million in cash compared to $18.2 million at December 31, 2010.  BDSI received an upfront payment of $30 million in early January 2012 with the signing of a license and development agreement with Endo Pharmaceuticals, Inc. (NASDAQ: ENDP) for BEMA Buprenorphine for the treatment of chronic pain.  A $15 million milestone payment, for granting of a patent extending the exclusi
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Fla. , May 22, 2015 ... Heart Institute recently traveled to Boston, ... procedure at the 2015 Heart Rhythm Society conference. ... together to focus on the ideas, people and ... Convergent is a hybrid, minimally invasive cardiac ...
(Date:5/22/2015)... 2015  The U.S. Food and Drug Administration,s ... first biosimilar product approved in the ... in the contract manufacturing organization (CMO) industry, according ... geared to the production of small-molecular drugs and ... The healthcare market research publisher,s report, Biopharmaceutical ...
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... For women who would like to have,children but who ... time in,their lives, the door to a new option has ... known as,vitrification, a quick freezing method, is a safe means ... exhaustive study yet on the,subject, the new study revealed that ...
... BioPharma, Inc.,(OTC: CBIA), is pleased to announce that ... for a Phase II study in 30 cancer,patients ... tract from radiation-induced mucositis. This new trial is,an ... as a novel,preventative, anti-mucositis agent., Oral and ...
Cached Medicine Technology:New Research Just Released: Women Can Now Safely Postpone Motherhood Until Time Is Right 2CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck 2
(Date:5/24/2015)... Dallas, TX (PRWEB) May 24, 2015 ... the Global and Chinese Enterokinase Industry, 2009-2019 Market Research ... as it is an exhaustive study on the present ... a special insight into the growing Chinese market of ... market and the overall status of the manufacturers in ...
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... May 24, 2015 Indiana Fiber Network, ... announces Midwest Telecom of America, Inc. (MTA) has selected ... to Cory Childs, IFN Enterprise Sales Manager, fiber route ... “IFN’s fiber transport provides MTA with the diverse ... their Tier 1 Internet and voice carriers located at ...
(Date:5/24/2015)... A report out just last month ... option for avoiding cardiovascular disease is exercise and maintaining ... single most powerful predictor of death and survival, even ... family history of premature death -- a finding that ... fitness. , The Importance of Cardiovascular Screening , The ...
(Date:5/23/2015)... Dr. David Benvenuti, an experienced plastic surgeon ... new article to his website that takes an ... explained in the fascinating blog, he has recently had ... , Known as “gauging,” the technique involves placing larger and ... said will eventually stretch the holes out to incredible sizes. ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2
... away and lodges in the lung (pulmonary embolism). The aim ... a clearer picture of the increased risk of venous thromboembolism ... doctors in how to prevent the condition arising after a ... out in the University,s Division of Epidemiology and Public Health. ...
... Long-term use of vitamin E and C supplements doesn,t reduce ... finds. "An estimated 20.5 million persons 40 and older ... wrote study author William G. Christen, of Brigham and Women,s ... a news release. Because oxidative damage is a prominent ...
... HealthDay Reporter , THURSDAY, Nov. 11 (HealthDay News) -- ... levels in check as you age is good for your ... suggests the connection between cholesterol and dementia later in life ... women followed for 32 years, Johns Hopkins researchers found that ...
... , WEDNESDAY, Nov. 10 (HealthDay News) -- Hospitals that ... reduced both complications and in-hospital deaths, a new study ... the Netherlands implemented a series of 11 checklists that ... the patient arrived at the hospital until discharge. ...
... 13% of the United States population, are living with ... grow. If current trends continue, there will not be ... To help address this crisis, the American Society of ... Workforce during its upcoming ASN Renal Week 2010 in ...
... scientists at the National Institute of Allergy and ... Health, sheds light on a poorly understood, acute ... develops in some HIV-infected individuals soon after they ... HIV-infected individuals whose immune systems are heavily damaged ...
Cached Medicine News:Health News:Combating cancer's double whammy 2Health News:Study Finds Vitamins E and C Don't Reduce Cataract Risk in Men 2Health News:High Cholesterol in Middle Age May Not Raise Dementia Risk for Women 2Health News:High Cholesterol in Middle Age May Not Raise Dementia Risk for Women 3Health News:Hospital Checklists Reduce Surgical Complications, Deaths: Study 2Health News:Hospital Checklists Reduce Surgical Complications, Deaths: Study 3Health News:ASN leads efforts to address growing crisis in kidney care 2Health News:NIH scientists unveil mechanisms of immune reconstitution inflammatory syndrome 2
Provides outstanding patient warming and safety throughout the hospital and is nearly half the size and one-third the weight of earlier units....
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care....
The product, which is comprised of a non-intrusive panty-liner, offers a simple to use classification tool that uses color identification for interpretation of the results....
The Affirm™ VPIII tests RNA probe technology offers a dependable, rapid means toward early identification and treatment of patients suffering from these pathogens....
Medicine Products: